electroCore (ECOR) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
electroCore (ECOR) has outperformed TriSalus Life Sciences (TLSI) over the past year, gaining 84.7% versus a loss of 14.8%. Over five years, ECOR leads with a -36.4% price change compared with -58.3% for TLSI. TriSalus Life Sciences is the larger company by market cap ($254.3 million vs $85.7 million), about 3.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ECOR | TLSI |
|---|---|---|
| Share price | $9.51 | $4.13 |
| Market cap | $85.74M | $254.30M |
| 1-day change | -2.16% | -2.82% |
| YTD return | +112.04% | -40.83% |
| 1-year return | +84.66% | -14.85% |
| 5-year return | -36.41% | -58.28% |
| EPS (TTM) | $-1.65 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.70 | $7.95 |
| 52-week low | $4.41 | $2.20 |
| Distance from 52-week high | -25.12% | -48.05% |
| Analyst consensus | none | none |
| Avg. price target upside | +101.58% | +151.82% |
| Average volume | 80.51K | 275.38K |
| Shares outstanding | 9.02M | 61.57M |
| Employees | 83 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TriSalus Life Sciences is about 3.0 times larger than electroCore by market value ($254.30M vs $85.74M).
- ECOR has outperformed TLSI by 99.5 percentage points over the past year.
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 83 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
ECOR vs TLSI FAQ
Which is bigger, electroCore or TriSalus Life Sciences?
TriSalus Life Sciences (TLSI) is larger, with a market capitalization of $254.30M compared with $85.74M for electroCore (ECOR).
Which stock has performed better over the past year, ECOR or TLSI?
ECOR returned +84.66% over the past 12 months, compared with -14.85% for TLSI (price return, excluding dividends). Past performance does not predict future results.
Are electroCore and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for electroCore and Medical Specialities for TriSalus Life Sciences.